Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]
Eur Urol. 2021 May;79(5):e158-e159.
doi: 10.1016/j.eururo.2021.01.031.
Epub 2021 Feb 9.
1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
2 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6 Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
7 Department of Medical Oncology, NYU Langone Health, New York, NY, USA.
8 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
9 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: iyerg@mskcc.org.